NPCE (NeuroPace) 10-Year Sortino Ratio: N/A (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NPCE NeuroPace Inc NPCE
69 GF Score
Price $14.25
GF Value $12.59
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is NeuroPace 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2026-09-15), NeuroPace's 10-Year Sortino Ratio is Not available.


NeuroPace  (NAS:NPCE) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


NeuroPace 10-Year Sortino Ratio Related Terms


NPCE vs SENS, CLPT, SGHT: 10-Year Sortino Ratio Comparison

For the Medical Devices subindustry, NeuroPace's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroPace 10-Year Sortino Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where NeuroPace's 10-Year Sortino Ratio falls into.


NPCE
69GF Score
NeuroPace Inc NPCE
10-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroPace 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $14.25 is trading 13.2% above its estimated GF Value™ of $12.59. GuruFocus considers NeuroPace to be Modestly Overvalued.

Key valuation signals for NPCE:

  • 10-Year Sortino Ratio: N/A
  • GF Value™: $12.59 vs. price of $14.25 (13.2% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
69GF Score

Get the complete analysis for NPCE

10-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.25
Price
$12.59
GF Value